Effects of GSK v Teva ripple after SCOTUS denies cert
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.
Latest news
Abbott sues former employee for alleged trade secrets theft
01-06-2023
Ex-scientist faces lawsuit for allegedly downloading thousands of files before leaving for a rival | Abbott seeks damages for ‘flagrant misconduct’ brought to its attention by successive employer.
